ReviewEndocrinology and metabolism (Seoul, Korea)2020
Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus.
Review in Endocrinology and metabolism (Seoul, Korea), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Serum testosterone and cardiometabolic risk in Nigerian men with type 2 diabetes: a cross-sectional study.Frontiers in endocrinology · 2026Article
- Nonlinear association between high-density lipoprotein cholesterol and carotid atherosclerosis risk in patients with type 2 diabetes: a retrospective analysis from China.European journal of medical research · 2025Article
- Review
- Associations between neutrophil-lymphocyte ratio with all-cause mortality, major adverse vascular events and progression of diabetic kidney disease in type 2 diabetes mellitus.Frontiers in endocrinology · 2025Article
- Predictive value of uric acid to albumin ratio for carotid atherosclerosis in type 2 diabetes mellitus: A retrospective study.PloS one · 2025Article
- The association between liver function tests abnormalities and type 2 diabetes mellitus patients in Saudi Arabia: a cross-sectional study.Frontiers in clinical diabetes and healthcare · 2025Article
- Factors Affecting Arterial Stiffness and Brachial-Ankle Pulse Wave Velocity in Patients With Type 2 Diabetes.Cureus · 2024Article
- Serum levels of soluble receptor activator for nuclear factor kB ligand play a crucial role in the association of osteoprotegerin with coronary artery disease.Experimental and therapeutic medicine · 2024Article
- Coronary Artery Calcium Score as a Sensitive Indicator of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus: A Long-Term Cohort Study.Endocrinology and metabolism (Seoul, Korea) · 2023Article
- Pathways of Coagulopathy and Inflammatory Response in SARS-CoV-2 Infection among Type 2 Diabetic Patients.International journal of molecular sciences · 2023Review
- Effects of hypertension on subcortical nucleus morphological alternations in patients with type 2 diabetes.Frontiers in endocrinology · 2023Observational
- Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus.Cardiovascular diabetology · 2022Article
- Topical Reappraisal of Molecular Pharmacological Approaches to Endothelial Dysfunction in Diabetes Mellitus Angiopathy.Current issues in molecular biology · 2022Review
- Visfatin is negatively associated with coronary artery lesions in subjects with impaired fasting glucose.Open medicine (Warsaw, Poland) · 2022Article
- Exploring Endothelial Colony-Forming Cells to Better Understand the Pathophysiology of Disease: An Updated Review.Stem cells international · 2022Review
- Article
- Serum netrin and VCAM-1 as biomarker for Egyptian patients with type IΙ diabetes mellitus.Biochemistry and biophysics reports · 2021Article
- The correlation between impaired thyroid hormone sensitivity and 10-year atherosclerotic cardiovascular disease (ASCVD) risk score in patients with type 2 diabetes mellitus.Diabetes & vascular disease researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well known that patients with type 2 diabetes mellitus (T2DM) are at an increased risk of morbidity and mortality from atherosclerotic cardiovascular (CV) complications. Previously, the concept that diabetes mellitus (DM) is a "coronary artery disease (CAD) risk equivalent" was widely accepted, implying that all DM patients should receive intensive management. However, considerable evidence exist for wide heterogeneity in the risk of CV events among T2DM patients and the concept of a "CAD risk equivalent" has changed. Recent guidelines recommend further CV risk stratification in T2DM patients, with treatment tailored to the risk level. Although imaging modalities for atherosclerotic cardiovascular disease (ASCVD) have been used to improve risk prediction, there is currently no evidence that imaging-oriented therapy improves clinical outcomes. Therefore, controversy remains whether we should screen for CVD in asymptomatic T2DM. The coexistence of T2DM and heart failure (HF) is common. Based on recent CV outcome trials, sodium glucose cotransporter-2 inhibitors and glucagon like peptide-1 receptor agonists are recommended who have established ASCVD, indicators of high risk, or HF because of their demonstrated benefits for CVD. These circumstances have led to an increasing emphasis on ASCVD and HF in T2DM patients. In this review, we examine the literature published within the last 5 years on the risk assessment of CVD in asymptomatic T2DM patients. In particular, we review recent guidelines regarding screening for CVD and research focusing on the role of coronary artery calcium, coronary computed tomography angiography, and carotid intima-media thickness in asymptomatic T2DM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.